Method of purifying botulinum toxin
Patent Information
- Application Number
- TW109145127
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-12-20
- Filing Date
- 2020-12-18
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2040-12-17
AI Technical Summary
Existing methods for purifying botulinum toxin suffer from low resolution, low yields, difficult handling, and scalability issues, and require reconstitution before administration, which can lead to contamination and dilution errors.
A method involving tangential flow filtration followed by a series of chromatography steps, including anion and cation exchange chromatography, and size exclusion chromatography, without precipitation or lyophilization, to purify botulinum toxin, resulting in a stable, ready-to-use solution.
The method achieves high-purity, high-yield botulinum toxin purification, eliminating the need for reconstitution and reducing contamination risks, while maintaining toxin activity and stability.
Smart Images

Figure TWG2TB001919865_001 
Figure TWG2TB001919865_002 
Figure TWG2TB001919865_003
Abstract
Description
[Technical Field]
[0001] This invention relates to the field of purifying neurotoxin protein molecules. Specifically, this invention relates to a method for purifying botulinum toxin. The purified botulinum toxin is suitable for therapeutic purposes, and specifically, for administration to patients to achieve desired therapeutic or cosmetic effects. [Previous Technology]
[0002] The following description of the technical background of the present invention is provided only to help understand the technical background of the present invention, and is not intended to acknowledge prior art that describes or constitutes the technical background of the present invention.
[0003] Immunologically, seven different botulinum neurotoxins have been characterized: botulinum neurotoxin serotypes A, B, C, D, E, F, and G, each distinguished by type-specific antibody neutralization. As an example, BOTOX® is a trademark of purified botulinum toxin type A neurotoxin complex, available from Allergan, Inc. (Irvine, California). BOTOX® is a popular injectable cosmetic treatment that temporarily reduces the appearance of fine lines and wrinkles.
[0004] Botulinum toxin (including type A toxin) is conventionally produced by the fermentation of Clostridium botulinum. This fermentation produces a culture solution containing, in addition to botulinum toxin molecules, intact bacteria, lysed bacteria, culture medium nutrients, and fermentation byproducts. Filtering the Clostridium botulinum culture solution removes intact and / or lysed cell components and, where applicable, other fermentation medium residues, producing a clear culture. The clear culture solution contains botulinum toxin molecules and various impurities that can be removed to obtain concentrated, purified botulinum toxin (e.g., BoNT / A1) suitable for formulation into botulinum toxin pharmaceutical compositions.
[0005] Existing methods for obtaining pharmaceutically suitable botulinum toxin compositions on a commercial scale typically employ multiple precipitation steps to separate the toxin complex from residual impurities in the fermentation process. For example, cold alcohol dissociation (e.g., Cohn's method) or precipitation is used to remove plasma proteins. Unfortunately, precipitation techniques for purifying botulinum toxin are plagued by low resolution, low yield, operational difficulties, challenges in control and / or validation, and a lack of scalability. Furthermore, drying botulinum toxin (e.g., by freeze-drying, precipitation, etc.) substantially reduces its toxicity. This poses a clinical concern because inactivated toxins can form toxoids and can be used to immunize patients against botulinum toxin.
[0006] However, currently approved botulinum toxin products in the United States (such as BOTOX COSMETIC®, DYSPORT®, XEOMIN®, and JEUVEAU®) are stored in lyophilized or freeze-dried form for stability reasons. These formulations require reconstitution with sterile saline solution by a physician before administration to the patient. This reconstitution step introduces risks of physician time loss, dilution errors, and contamination. Botulinum toxin providers must also train physicians to ensure the reconstitution procedure is properly performed.
[0007] Therefore, in order to obtain a high-purity, highly active, and pharmaceutically suitable botulinum toxin composition that is free of, substantially free of, or substantially free of animal products and does not require reconstitution before administration to patients, a controlled, scalable, high-yield method is needed to purify botulinum toxin from fermentation media. [Summary of the Invention]
[0008] In one embodiment, the present invention relates to a method for purifying botulinum toxin, comprising purifying the toxin from a solution containing the toxin, wherein the method does not involve precipitation, centrifugation or lyophilization.
[0009] In some embodiments, the botulinum toxin is serotype A. In some embodiments, the resulting purified botulinum toxin is free of, substantially free of, or substantially free of botulinum toxin complexes. In some embodiments, the resulting purified botulinum toxin is free of, substantially free of, or substantially free of animal products, including human albumin.
[0010] In some embodiments, purification includes a filtration step, preferably a tangential flow filtration step. In some embodiments, the filtration step uses a hollow fiber filter. In some embodiments, purification includes contacting a first chromatography column with a solution containing the toxin to generate a toxin-containing dissociated fraction. In some embodiments, the first chromatography column comprises an anion exchange chromatography column. In some embodiments, the anion exchange chromatography column comprises Q agarose. In some embodiments, purification further includes collecting the toxin-containing dissociated fraction, wherein the toxin-containing dissociated fraction does not adsorb to the first stationary phase.
[0011] In some embodiments, purification further includes contacting a second chromatography column with the toxin-containing lysate. In some embodiments, the second chromatography column comprises a cation exchange chromatography column. In some embodiments, the cation exchange chromatography column comprises SP agarose. In some embodiments, purification further comprises dissociating botulinum toxin from the second chromatography column to produce a first toxin-containing lysate.
[0012] In some embodiments, purification further comprises filtering a first toxin-containing elution buffer to produce a toxin-containing retentate. In some embodiments, filtering the first toxin-containing elution buffer comprises buffer exchange. In some embodiments, filtering the first toxin-containing elution buffer is a process of separating botulinum toxin molecules from non-toxin proteins to produce free toxin molecules.
[0013] In some embodiments, purification further includes contacting a third chromatography column with a toxin-containing retentate. In some embodiments, the third chromatography column comprises a second anion exchange chromatography column. In some embodiments, the second anion exchange chromatography column comprises Q agarose. In some embodiments, purification further comprises dissociating botulinum toxin from the third chromatography column to produce a second toxin-containing precipitate.
[0014] In some embodiments, purification further includes contacting the fourth chromatography column with a second toxin-containing elution solution. In some embodiments, the toxin-containing elution solution is injected directly onto the fourth chromatography column. In some embodiments, the third chromatography column is interconnected with the fourth chromatography column.
[0015] In some embodiments, the fourth chromatography column comprises a size exclusion chromatography column. In some embodiments, the size exclusion chromatography column comprises a gel filtration chromatography column. In some embodiments, the gel filtration chromatography column comprises Superdex 200. In some embodiments, purification further comprises dissociating botulinum toxin from the fourth chromatography column to produce purified botulinum toxin.
[0016] In another embodiment, a method for purifying botulinum toxin from a solution containing the toxin comprises: (a) filtering the solution containing the toxin; (b) contacting a first chromatography column with the filtered toxin-containing solution from (a), wherein the first chromatography column is an ion-exchange chromatography column; (c) collecting the toxin-containing elutile, wherein the toxin-containing elutile flows through the first chromatography column without adsorbing to the stationary phase; (d) contacting a second chromatography column with the toxin-containing elutile, wherein the second chromatography column is an ion-exchange chromatography column; and (e) eluting the botulinum toxin from the second chromatography column to produce a first toxin-containing solution. (f) Filtering the first toxin-containing precipitate to produce a toxin-containing retentate; (g) Contacting a third chromatography column with the toxin-containing retentate from filtration (f), wherein the third chromatography column is an ion exchange column; (h) Dissociating botulinum toxin from the third chromatography column to produce a second toxin-containing precipitate; (i) Contacting a fourth chromatography column with the second toxin-containing precipitate, wherein the fourth chromatography column is a size exclusion chromatography column; and (j) Dissociating botulinum toxin from the fourth chromatography column to produce purified botulinum toxin, wherein the method does not involve precipitation, centrifugation, or lyophilization of botulinum toxin.
[0017] In some embodiments, the botulinum toxin comprises botulinum neurotoxin serotype A. In some embodiments, the resulting purified botulinum toxin is free of, substantially free of, or substantially free of botulinum toxin complexes. In some embodiments, the resulting purified botulinum toxin is free of, substantially free of, or substantially free of animal products, including human albumin.
[0018] In some embodiments, the first chromatography column comprises an anion exchange chromatography column. In some embodiments, the first chromatography column comprises Q agarose.
[0019] In some embodiments, the second chromatography column comprises a cation exchange chromatography column. In some embodiments, the second chromatography column comprises SP agarose.
[0020] In some embodiments, the first chromatography column comprises an anion exchange chromatography column and the second chromatography column comprises a cation exchange chromatography column. In some embodiments, the first chromatography column comprises Q agarose and the second chromatography column comprises SP agarose.
[0021] In some embodiments, the third chromatography column comprises an anion exchange chromatography column. In some embodiments, the third chromatography column comprises Q agarose.
[0022] In some embodiments, the fourth chromatography column comprises a gel filtration column. In some embodiments, the fourth chromatography column comprises Superdex 200.
[0023] In some embodiments, the third chromatography column comprises an anion exchange chromatography column and the fourth chromatography column comprises a gel filtration chromatography column. In some embodiments, the third chromatography column comprises Q agarose and the fourth chromatography column comprises Superdex 200. In some embodiments, a second toxin-containing elution solution is injected directly onto the fourth chromatography column. In some embodiments, the third chromatography column and the fourth chromatography column are interconnected.
[0024] In some embodiments, the first chromatography column is an anion exchange chromatography column, the second chromatography column is a cation exchange chromatography column, the third chromatography column is a second anion exchange chromatography column, and the fourth chromatography column is a gel filtration chromatography column. In one embodiment, the first chromatography column contains Q agarose, the second chromatography column contains SP agarose, the third chromatography column contains Q agarose, and the fourth chromatography column contains Superdex 200.
[0025] In some embodiments, the first, second, third and fourth chromatography columns are disposable chromatography systems.
[0026] In some embodiments, filtration (f) separates botulinum toxin protein molecules from non-toxin proteins to produce free toxin molecules. In some embodiments, filtration (f) includes buffer exchange.
[0027] In some embodiments, the solution containing botulinum toxin is free of, substantially free of, or substantially free of animal products. In some embodiments, purification includes contacting the botulinum toxin with a buffer solution, wherein the buffer solution has been filtered to reduce the bioburden.
[0028] In another embodiment, the present invention relates to a purified botulinum toxin produced by purifying the toxin from a solution containing the toxin, wherein the method includes excluding precipitation, centrifugation, or lyophilization. In some embodiments, the purified botulinum toxin is serotype A. In some embodiments, the purified botulinum toxin is free of, substantially free of, or substantially free of toxin complexes. In some embodiments, the purified botulinum toxin is free of, substantially free of, or substantially free of animal products, including human albumin.
[0029] In another embodiment, the present invention relates to a composition comprising purified botulinum toxin present in a phosphate-containing buffer solution. In some embodiments, the buffer solution further comprises acetate. In some embodiments, the buffer solution further comprises at least one chloride ion source. In some embodiments, the at least one chloride ion source comprises sodium chloride. In some embodiments, the buffer solution further comprises at least one surfactant. In some embodiments, the surfactant is polysorbate 20.
[0030] In some embodiments of the composition according to the invention, the composition contains botulinum toxin, botulinum toxin neurotoxin serotype A. In some embodiments, the composition contains no, substantially no, or substantially no botulinum toxin complex. In some embodiments, the composition contains no, substantially no, or substantially no animal product. In some embodiments, the composition contains no, substantially no, or substantially no human albumin. In some embodiments, the pH of the composition is between about 6.6 and 6.9.
[0031] The following embodiments are illustrative and explanatory, and are not intended to be restrictive.
Implementation Method
[0032] Cross-referencing of related applications
[0033] This application claims priority to U.S. Provisional Application No. 62 / 951,828, filed on December 20, 2019, pursuant to 35 USC § 119(e), which is incorporated herein by reference in its entirety.
[0034] Embodiments of the present invention will be described more fully below. However, the present invention may be implemented in different forms and should not be considered as limited to the embodiments set forth herein. In fact, these embodiments are provided so that the invention will thoroughly and completely convey its scope to those skilled in the art. It should be understood that the present invention is not limited to specific methods, reagents, compound compositions, or biological systems, and such modifications are of course possible. The terminology used in this specification is for the purpose of describing particular embodiments only and is not intended to be restrictive.
[0035] Unless otherwise defined, all terms used herein (including technical and scientific terms) shall have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. It should be further understood that terms (such as those as defined in common dictionaries) shall be interpreted in accordance with their meaning in the context of this application and in the relevant art, and shall not be interpreted in an idealized or overly formal sense unless expressly defined herein. Even if such terms are not expressly defined below, they shall be interpreted according to their common meaning.
[0036] Furthermore, when describing the features or features of the present invention in accordance with the Markush groups, those skilled in the art will recognize that the present invention is therefore also described in accordance with any individual member or subgroup of the Markush groups.
[0037] As will be understood by those skilled in the art, for any and all purposes, especially for the purpose of providing a written description, all scopes disclosed herein also encompass any and all possible subscopes and combinations thereof. Any listed scope can be readily considered sufficiently descriptive and such that the same scope can be decomposed into at least two equal halves, one-thirds, one-quarters, one-fifths, one-tenths, etc. As a non-limiting example, each scope discussed herein can be readily decomposed into a lower third, a middle third, and an upper third, etc. As will also be understood by those skilled in the art, all terms such as "at most," "at least," "greater than," "less than," etc., include the stated value and refer to a scope that can subsequently be decomposed into subscopes, as discussed above. Finally, as will be understood by those skilled in the art, a scope includes each individual member. Thus, by way of example, a group having 1-3 cells refers to a group having 1, 2, or 3 cells. Similarly, a group having 1-5 cells refers to a group having 1, 2, 3, 4, or 5 cells, and so on.
[0038] Unless the context otherwise indicates, it specifically means that the different features of the invention described herein can be used in any combination. Furthermore, the invention also contemplates that in some embodiments, any feature or combination of features set forth herein may be excluded or omitted. For illustrative purposes, if the specification states that a complex comprises components A, B, and C, it specifically means that any one of A, B, or C, or any combination thereof, may be omitted and not claimed individually or in any combination.
[0039] Unless otherwise expressly indicated, all specified embodiments, features and terms are intended to include the embodiments, features or terms and their biological equivalents.
[0040] All patents, patent applications, provisional applications, and publications mentioned or cited herein, including all figures and tables, are incorporated herein by full reference, to the extent that they do not contradict the explicit teachings of this specification. Definitions
[0041] As used herein, unless explicitly stated otherwise, the singular forms “a / an” and “the” represent both singular and plural.
[0042] As used herein, “and / or” means and covers all possible combinations of any one or more of the relevant listed items, as well as the lack of combinations (when interpreted as an alternative (“or”).
[0043] Unless explicitly stated otherwise, all numerical values are preceded by the terms "about" or "approximately". The terms "about" or "approximately" mean that the figures covered are not limited to the exact figures set forth herein, and mean figures that are substantially close to said figures without departing from the scope of the invention. As used herein, "about" or "approximately" will be understood by those skilled in the art and will vary to some extent depending on the context in which it is used. If a term is not clearly defined by those skilled in the art (where the context in which it is used is given), then "about" or "approximately" means at most plus or minus 10%, 5%, 1%, or 0.1% of that particular term.
[0044] As used herein, “free from” or “completely free from” means that the substance cannot be detected or its presence cannot be confirmed within the detection range of the instrument or method being used.
[0045] As used herein, "substantially free of" means that only trace amounts of the substance can be detected. In this invention, "substantially free of" means that the substance is present in a concentration of less than 0.1% by weight, preferably less than 0.01% by weight, and most preferably less than 0.001% by weight in the entire composition.
[0046] As used herein, "substantially free of" means that the substance is present in the whole composition in an amount of less than 5% by weight, preferably less than 2% by weight, and most preferably less than 1% by weight.
[0047] As used herein, "botulinum toxin" means a neurotoxin produced by Clostridium botulinum, and botulinum toxin (or its light or heavy chain) recombined from non-clostridium species. As used herein, the phrase "botulinum toxin" encompasses botulinum toxin serotypes A, B, C, D, E, F, and G. "Botulinum toxin" also encompasses "modified botulinum toxin".
[0048] As used herein, "botulinum toxin complex" or "toxin complex" encompasses a complex released by Clostridium bacteria containing botulinum toxin protein molecules (approximately 150 kDa for all serotypes) and one or more associated non-toxin proteins. The botulinum toxin complex (e.g., with a molecular weight of approximately 300 kDa, 500 kDa, or 900 kDa) contains non-toxin hemagglutinin proteins ("NTH proteins") and non-toxin non-hemagglutinin proteins ("NTNH proteins"). Therefore, a botulinum toxin complex may contain botulinum toxin molecules (the neurotoxic component) and one or more NTH and / or NTNH proteins. These two types of non-toxin proteins stabilize the toxin molecule to prevent denaturation and prevent digestive acid ingestion. Furthermore, larger (300 kDa and larger) botulinum toxin complexes can diffuse more slowly from the intramuscular injection site compared to botulinum toxin proteins.
[0049] As an example of a toxin complex, botulinum toxin type A complex can be produced by Clostridium bacteria in 900 kDa, 500 kDa, and 300 kDa forms. Botulinum toxin type B and C1 are produced in the form of a 500 kDa complex. Botulinum toxin type D is produced in the form of a 300 kDa and 500 kDa complex. Finally, botulinum toxin type E and F are produced in the form of a complex of approximately 300 kDa.
[0050] When referring to botulinum toxin type A1 neurotoxin, it is known that non-toxin proteins dissociate from botulinum toxin protein molecules (approximately 150 kDa) at pH values greater than approximately 7. Therefore, the toxin complex can be dissociated into botulinum toxin proteins and hemagglutinin proteins by methods such as column chromatography, which separate the toxin complex in a suitable buffer at a pH of approximately 7-8. However, it is known that botulinum toxin proteins are unstable after the removal of NTH and / or NTNH hemagglutinin proteins, and that the toxin loses its toxicity with increasing pH and temperature, or as a result of surface stretching or drying (e.g., during lyophilization or precipitation). Furthermore, unless a stabilizer is present, the toxin loses its specific activity upon dilution (e.g., during culture, fermentation, and purification).
[0051] As used herein, "modified botulinum toxin" means botulinum toxin in which at least one amino acid has been missing, modified, or substituted compared to native botulinum toxin. Additionally, modified botulinum toxin may be a recombinant neurotoxin, or a derivative or fragment of a recombinant neurotoxin. Modified botulinum toxin retains at least one biological activity of native botulinum toxin, such as the ability to bind to botulinum toxin receptors or the ability to inhibit the release of neurotransmitters from neurons. One example of modified botulinum toxin is a botulinum toxin having a light chain from a botulinum toxin serotype (such as serotype A) and a heavy chain from a different botulinum toxin serotype (such as serotype B). Thus, modified botulinum toxin may include light and heavy chains from two different serotypes selected from any one of serotypes A, B, C, D, E, F, or G. Another example of modified botulinum toxin is botulinum toxin coupled with neurotransmitters.
[0052] As used herein, "purified botulinum toxin," "pure toxin," "free botulinum toxin," "free toxin," or "botulinum toxin protein" are defined as botulinum toxin that is separated or substantially separated from other proteins (including NTH and / or NTNH proteins that form botulinum toxin complexes). The purity of purified botulinum toxin may be greater than 95%, preferably greater than 99%.
[0053] As used herein, “culture medium” or “fermentation medium” means any culture medium used to cultivate bacteria for the purpose of producing a seed culture for inoculating a production medium, or a production medium in which bacteria grow and produce their toxins.
[0054] As used herein, "APF" ("Animal Product Free"), "Substantially Animal Product Free", or "Substantially Animal Product Free" respectively encompass "Animal Protein Free", "Substantially Animal Protein Free", or "Substantially Animal Protein Free" and mean the absence, substantial absence, or substantial absence of products or compounds of blood origin, blood mix, or other animal origin. In this context, "Animal Free", "Substantially Free", and "Substantially Animal Product Free" correspond to the definitions provided above. "Animal" means mammal (such as humans), bird, reptile, fish, insect, arachnid, or other animal species. "Animal" does not include microorganisms, such as bacteria. Therefore, APF culture media or methods or basic APF culture media or methods within the scope of this invention may include botulinum toxin or Clostridium botulinum bacteria. For example, an APF method or basic APF method means a method that is free or substantially free of animal-derived proteins (such as immunoglobulins, human albumin, meat digests, meat by-products, and milk or dairy products or digests). Therefore, an example of the APF method is a method that does not include meat and dairy products or meat or dairy by-products (such as bacterial culture or bacterial fermentation methods).
[0055] As used herein, "bioload" means bacteria that are alive on surfaces, within devices, or in solutions that have not been sterilized. For example, embodiments of the present invention include filtering buffer solutions to reduce "bioload" bacteria that are alive in the buffer solution or have transferred from surfaces in contact with the solution (e.g., glassware surfaces) into the solution.
[0056] As used herein, "tangential flow filtration" and "TFF" refer to filtration modes suitable for clarifying, concentrating, and purifying biological materials (e.g., proteins). In TFF, a solution or suspension containing macromolecules or biological materials is pumped tangentially along the membrane surface. The applied pressure forces a portion of the solution through the pores in the membrane. This solution is referred to herein as the "permeate" (or "filtrate"). Macromolecules, biological materials, and particles that are too large to pass through the membrane pores are retained on the upstream side. This solution is referred to herein as the "retained material". Compared to conventional filtration methods, the retained material does not accumulate on the membrane surface. Instead, it is swept across the membrane surface by the tangential flow of the fluid. See, for example, L. Schwartz and K. Seeley, Introduction to Tangential Flow Filtration for Laboratory and Process Development Applications, PALL LIFE SCIENCES (2002), https: / / laboratory.pall.com / content / dam / pall / laboratory / literature-library / non-gated / id-34212.pdf.
[0057] As used herein, "permeate" means a solution, suspension, or component thereof that passes through the pores of a filter or membrane (e.g., a filtration membrane, tangential flow filtration membrane, ultrafiltration membrane, microfiltration membrane, or hollow fiber filter), as well as a solution that has passed through or crossed a filter or membrane. Generally, solvent and solute molecules smaller than the pore size of the filter or membrane will pass through the filter or membrane, while molecules larger than the pore size will not.
[0058] As used herein, "toxin-containing permeation fluid" refers to a permeation fluid containing botulinum toxin molecules, such as when the filter pore size is larger than the botulinum toxin molecules, allowing the botulinum toxin molecules to cross the filter.
[0059] As used herein, "retained material" means a solution, suspension, or component thereof that does not cross a filter or membrane. For example, in the case of tangential flow filtration, the retained material is a component or portion of a solution or suspension that flows tangentially along the filter or membrane but does not cross it. Generally, molecules larger than the pore size of the filter or membrane do not cross it.
[0060] As used herein, "toxin-containing retrieval material" means retrieval material containing botulinum toxin molecules, such as when the filter pore size is smaller than botulinum toxin molecules, so that botulinum toxin molecules cannot cross the filter.
[0061] As used herein, "transmembrane pressure" or "TMP" refers to the pressure gradient applied along the length of the filter membrane to facilitate the flow of fluid and filterable solute through or across the filter or membrane.
[0062] As used herein, "diafiltration" refers to a specific type of filtration in which the retentate is diluted with a solvent and then filtered again to reduce the concentration of soluble permeate components. Diafiltration may or may not cause an increase in the concentration of the retentate components (including proteins such as BoNT / A). For example, in continuous diafiltration, the solvent is continuously added to the retentate at the same rate as the permeate is generated. In this case, the volume of the retentate and the concentration of the retentate components do not change during the process. On the other hand, in discontinuous or sequential dilution diafiltration, the solvent is added to the retentate side after the filtration step; if the volume of solvent added to the retentate side is less than the volume of permeate generated, the concentration of the retentate components will be higher than that of the original solution. Diafiltration can be used to alter the pH, ionic strength, salt composition, or other properties of solutions or suspensions of macromolecules such as proteins, such as BoNT / A. See, for example, L. Schwartz, Diafiltration: A Fast, Efficient, Method for Desalting, or Buffer Exchange of Biological Samples, PALL LIFE SCIENCES (2003), https: / / laboratory.pall.com / content / dam / pall / laboratory / literature-library / non-gated / 02.0629_Buffer_Exchange_STR.pdf (last accessed on December 8, 2019).
[0063] As used herein, "diafiltration volume" or "DV" refers to the total volume exchanged during diafiltration. A single DV is equal to the volume of retentate at the start of diafiltration. For example, if the initial solution volume is one liter, the permeate volume produced during diafiltration is approximately one liter, and the retentate is maintained at or restored to a volume of 1 L (e.g., using a buffer solution), then the initial solution or suspension has been filtered or washed with one DV. Continuous diafiltration allows for multiple DV exchanges. For example, if the initial retentate volume is one liter, and the permeate volume produced during diafiltration is approximately five liters, then the initial solution or suspension has been filtered or washed with five DVs.
[0064] As used herein, “microfiltration” refers to a type of filtration that typically uses membrane pore sizes ranging from about 0.1 µm to about 10 μm and larger. See, for example, Munir Cheryan, Ultrafiltration and Microfiltration Handbook (2nd edition, 1998).
[0065] As used herein, "ultrafiltration" refers to a type of filtration that typically uses membrane pore sizes ranging from about 0.1 µm to about 0.01 μm and smaller. Alternatively, the nominal membrane pore size can be expressed in terms of molecular weight, for example, about 30 kDa and lower to about 750 kDa and lower, preferably 50 kDa and lower or 30 kDa and lower. It can refer to any such technique that subjects a solution or suspension to a semipermeable membrane to retain large molecules while allowing solvent and small solute molecules to pass through. Ultrafiltration can be used to concentrate large molecules (e.g., proteins, such as BoNT / A) in a solution or suspension. See, for example, Munir Cheryan, Ultrafiltration and Microfiltration Handbook (2nd edition, 1998).
[0066] As used herein, “chromatography” or “chromatographic separation” refers to a physical separation method in which components to be separated (e.g., proteins) are partitioned between two phases: a stationary phase and a mobile phase. The molecules to be separated are dissolved in the mobile phase and travel through the stationary phase (e.g., porous gels, charged polymer beads, etc.). Separation is possible because different molecules in the sample will exhibit different affinities to the stationary phase, causing similar molecule separation. Molecules with a higher affinity for the stationary phase tend to move through the stationary phase more slowly than molecules with a weaker affinity. When applied to proteins (e.g., botulinum toxin), chromatographic separation can separate proteins based on many different properties. For example, in gel filtration chromatography, proteins in the mobile phase are separated based on size because proteins of different sizes travel through the porous stationary phase, where smaller proteins become trapped, slowing their movement. In ion exchange chromatography, proteins are separated based on their charge and coulombic interactions with the stationary phase.
[0067] As used herein, "chromatographic column" or simply "column" means a component containing a chromatographic matrix (e.g., a stationary or solid phase) configured such that a mobile phase (e.g., a fluid sample or buffer solution) can pass through the column, thereby passing through the stationary phase held in place by the column. A non-limiting example of such a column is a column available from GE Healthcare. See Chromatography Products: Chromatography columns, systems, resins, and buffer management solutions, GE HEALTHCARE, https: / / www.gelifesciences.com / en / us / shop / chromatography (last accessed December 9, 2019).
[0068] As used herein, "dissolved portion" refers to a portion of the mobile phase collected upon exiting the column. The composition of the "dissolved portion" will vary based on the time of its collection. Faster mobile "dissolved portions" collected earlier will contain relatively higher concentrations of molecules that have moved faster through the stationary phase; slower mobile "dissolved portions" collected later will contain relatively higher concentrations of molecules that have moved slower through the stationary phase.
[0069] As used herein, "toxin-containing elution fraction" means the elution fraction collected from the chromatography column during the time period during which botulinum toxin molecules (e.g., BoNT / A molecules) leave the column via the mobile phase.
[0070] As used herein, "ion-exchange chromatography" or "IEX" refers to a chromatographic separation technique that separates molecules based on the polarity and magnitude of their molecular charges (e.g., +2, +1, neutral, -1, -2, etc.). IEX retains analyte molecules (e.g., proteins) on a stationary phase based on the degree of coulombic interaction between the analyte molecules and the stationary phase. The stationary phase surface exhibits ionic functional groups that interact with analyte ions (e.g., botulinum toxin) carrying opposite charges. To achieve electroneutrality, these stable charges interact with the exchangeable opposite ions in the mobile phase. The analyte molecules compete with these exchangeable opposite ions for binding. The analyte molecules are retained or "dissolved" based on their charges. Initially, molecules that are not bound or weakly bound to the stationary phase are washed away first. See, for example, Ion Exchange Chromatography: Principles and Methods, GE HEALTHCARE (2016), https: / / cdn.gelifesciences.com / dmm3bwsv3 / AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=13101 (last accessed on December 9, 2019).
[0071] As used herein, "anion exchange chromatography" or "AIEX" refers to a type of ion exchange chromatography in which anionic analyte molecules (e.g., proteins) are retained on a cation stationary phase. See, for example, Ion Exchange Chromatography: Principles and Methods, GE HEALTHCARE (2016), https: / / cdn.gelifesciences.com / dmm3bwsv3 / AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=13101 (last accessed December 9, 2019).
[0072] As used herein, "cation exchange chromatography" or "CIEX" refers to a type of ion exchange chromatography in which cationic analyte molecules (e.g., proteins) are retained on an anionic stationary phase. See, for example, Ion Exchange Chromatography: Principles and Methods, GE HEALTHCARE (2016), https: / / cdn.gelifesciences.com / dmm3bwsv3 / AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=13101 (last accessed December 9, 2019).
[0073] As used herein, "dissociation" refers to the desorption of molecules bound to the stationary phase by altering the solution conditions within the chromatography column. This can be achieved by increasing the concentration of exchangeable ions or by changing the pH to affect the binding affinity of the analyte. Molecules that lose their affinity for the stationary phase and enter the mobile phase "dissociate" from the column.
[0074] As used herein, "liquidation solution" or "washing solution" refers to a reagent, typically a solution, used to regulate the adsorption of an analyte (e.g., botulinum toxin molecules) onto a stationary phase and / or to remove unbound substances from the stationary phase. The dissociation characteristics of a liquidation solution can depend on factors such as pH, ionic strength, and detergent strength, as well as other factors.
[0075] As used herein, "dissolution solution" means a solution (e.g., a washing solution or a buffer solution) containing unbound substances (including "dissolved" or desorbed analyte molecules, such as botulinum toxin molecules) that travel through the stationary phase and are separated from the column by chromatography.
[0076] As used herein, "toxin-containing elution solution" refers to a mobile phase containing dissolved botulinum toxin molecules that exits the column via a chromatography separation column.
[0077] As used herein, "gel filtration chromatography" or "gel filtration" refers to a type of size exclusion chromatography that can be used to fractionate molecules (e.g., proteins, protein complexes, polysaccharides, nucleic acids, small molecules, etc.) in a sample into fractions, each having a specific size range. Alternatively, "gel filtration" can remove all molecules larger than a specific cutoff size from a sample. In a gel filtration chromatography column, the stationary phase comprises a porous matrix (e.g., beads), and the mobile phase is a solution (e.g., a buffer solution) flowing around the matrix. The matrix may have a defined pore size range, referred to as the "fractionation range." Molecules and complexes that are too large to enter the pores remain in the mobile phase and travel through the column with the buffer solution. Smaller molecules and complexes that can travel into the pores enter the stationary phase and travel a longer path through the gel filtration column (i.e., through the pores, rather than around the beads). Molecules that can enter the stationary phase are fractionated according to size. Smaller molecules will migrate through the pores at a slower rate than larger molecules that are not easily able to enter the pores. Therefore, the larger the molecule, the faster it dissolves. Thus, sample components exceeding the fractionation range will dissolve before those within the fractionation range. See, for example, Size Exclusion Chromatography: Principles and Methods, GE HEALTHCARE (2018), https: / / cdn.gelifesciences.com / dmm3bwsv3 / AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=11639 (last accessed December 9, 2019).
[0078] As used herein when referring to components of a chromatography system, "disposable" means a component prepared for replacement or disposal after each use and not intended for reuse in the system. Fermentation medium
[0079] Referring now to Figure 1, method 100 for purifying botulinum toxin may include obtaining 104 a solution (e.g., fermentation medium) containing botulinum toxin (e.g., BoNT / A). In some embodiments, the solution may be a fermentation medium, preferably a supernatant from a fermentation medium, which contains intact Clostridium botulinum cells, lysed bacteria, culture medium nutrients (e.g., plant protein) and fermentation byproducts. In some embodiments, the fermentation medium may be substantially free of, substantially free of, or free of animal products (i.e., "APF" fermentation medium), such as the fermentation medium described in U.S. Provisional Patent Application No. 62 / 951,549, which is also filed.
[0080] Botulinum toxin can be isolated and purified from fermentation media using protein purification methods known to those generally skilled in protein purification techniques. See, for example, Munir Cheryan, Ultrafiltration and Microfiltration Handbook (2nd edition, 1998); Ozutsumi et al., 49 Appl. Envtl. Microbiol. 939 (1985); GE Healthcare, Strategies for Protein Purification Handbook (2010).
[0081] The purification method of the present invention as described herein may include purifying botulinum toxin complexes (e.g., 900 kDa complexes) with stability greater than 150 kDa botulinum toxin protein molecules, followed by separating the toxin protein molecules from non-toxin proteins (i.e., NTH and / or NTNH proteins) and further purifying them to obtain purified botulinum toxin (approximately 150 kDa) product without using any precipitation, centrifugation, or lyophilization steps. The product toxin solution may be free of, substantially free of, or substantially free of toxin complexes and / or animal products. Furthermore, since precipitation, lyophilization, or centrifugation steps are not required, botulinum toxin can be recovered from the solution; in contrast, powder must be reconstituted by the end user before being administered to the patient. Filtration 1
[0082] Referring again to Figure 1, the method may include a first filtration ("filtration 1") 106, which includes a filtration medium or culture solution to remove intact or dissolved bacteria, spores (e.g., Clostridium botulinum spores), and debris to provide a toxin-containing permeate 107. The toxin-containing permeate 107 contains botulinum toxin and various impurities and can be processed to obtain concentrated botulinum toxin (e.g., BoNT / A).
[0083] In a particular embodiment, the first filtration 106 comprises removing intact or dissolved Clostridium botulinum cells (or components thereof) from the fermentation medium using any suitable filtration technique (e.g., diafiltration, tangential flow microfiltration, tangential flow ultrafiltration, hollow fiber filtration, etc.). Filtration techniques for purifying biomolecules (such as proteins) are well known in this art. See, for example, L. Schwartz and K. Seeley, Introduction to Tangential Flow Filtration for Laboratory and Process Development Applications, PALL LIFE SCIENCES (2002), https: / / laboratory.pall.com / content / dam / pall / laboratory / literature-library / non-gated / id-34212.pdf (last accessed December 9, 2019); Munir Cheryan, Ultrafiltration and Microfiltration Handbook (2nd edition, 1998). In one embodiment, the first filtration 106 comprises tangential flow microfiltration.
[0084] In some embodiments, the first filtration step 106 may use a filter (e.g., a hollow fiber filter, a tangential flow membrane, etc.), wherein at least the solvent and botulinum toxin molecules or toxin complexes pass through the filter to generate a toxin-containing permeate 107, while intact or lysed cells (if present) do not pass through the filter and are retained in the retentate. In some embodiments, the filter comprises pores with a diameter between about 0.1 µm and 10 µm (e.g., about 0.2 µm). In one embodiment, the filter is a hollow fiber filter.
[0085] In some embodiments, the first filtration step 106 may further include concentrating the toxin-containing permeate 107 by any suitable method (e.g., diafiltration) and recovering additional botulinum toxin molecules from the self-retaining material and / or the toxin-containing permeate 107. Filtration 2
[0086] Referring again to Figure 1, the method may further include a second filtration ("filtration 2") 108 for removing fermentation medium residues (e.g., small peptides, carbohydrates, etc.) from the self-contained toxin permeate 107. This step may include any suitable filtration technique (e.g., diafiltration, tangential flow microfiltration, tangential flow ultrafiltration, hollow fiber filtration, etc.). In one embodiment, the second filtration 108 for removing fermentation medium residues includes ultrafiltration using a tangential flow filter (e.g., a hollow fiber filter) with a pore size that allows fermentation medium residues to pass through the filter while retaining botulinum toxin molecules and / or toxin complexes. For example, in some embodiments, the filter pore size may be 150 kDa or less, 100 kDa or less, or 50 kDa or less. In this case, botulinum toxin molecules or botulinum toxin complexes are retained in the retentate from the second filtration 108, producing a clear culture 110 containing botulinum toxin molecules or botulinum toxin complexes, but containing no, substantially no, or substantially no intact or dissolved Clostridium botulinum cells (or components thereof), as well as fermentation medium residues (e.g., small peptides, carbohydrates, etc.).
[0087] In some embodiments, the clarified culture 110 can be collected and further purified in subsequent processing steps without precipitating botulinum toxin molecules or toxin complexes from solution at any time during the purification process. Advantageously, this increases the overall method yield, preserves toxin activity, and eliminates the need for end-user reconstitution of the lyophilized drug. Column chromatography: First chromatographic separation
[0088] Still referring to Figure 1, some embodiments of method 100 further include purifying the clarified culture 110 using a first chromatographic separation 112 to produce a first toxin-containing lysate 114. The purpose of this step is to separate the botulinum toxin complex present in the clarified culture 110 from nucleic acids (e.g., DNA and RNA). The first chromatographic separation 112 may include any suitable chromatographic separation technique (e.g., ion exchange chromatography (including anion exchange chromatography or cation exchange chromatography), gel filtration chromatography, high performance liquid chromatography, affinity chromatography, etc.). In some embodiments, the first chromatographic separation may include anion exchange chromatography (AIEX). In one embodiment, the first chromatographic separation includes performing AIEX on Q agarose.
[0089] The first chromatographic separation 112 may involve contacting a first chromatographic column with a clarified culture 110 containing botulinum toxin or a toxin complex. A mobile phase (containing the clarified culture 110) may flow through the first stationary phase to separate the botulinum toxin from other residual impurities (e.g., nucleic acids). The first stationary phase may contain any suitable chromatographic matrix (e.g., an agarose bead-based medium, such as Q agarose FF (GE Healthcare)).
[0090] In a particular embodiment, for column chromatography, the clarified culture 110 can be adjusted (e.g., by dilution in a buffer solution or by buffer exchange). In one particular embodiment, the clarified culture 110 can be adjusted in a phosphate buffer with a pH less than or equal to about 7.5 (preferably less than or equal to about 7, more preferably about 6.1). In some embodiments, the clarified culture 110 can be adjusted in a phosphate buffer with a pH of about 7.5, about 7.4, about 7.3, about 7.2, about 7.1, about 7.0, about 6.9, about 6.8, about 6.7, about 6.6, about 6.5, about 6.4, about 6.3, about 6.2, about 6.1, about 6.0, about 5.9, about 5.8, about 5.7, about 5.6, or about 5.5.
[0091] In a particular embodiment, the first chromatographic separation 112 may further comprise washing the botulinum toxin or toxin complex through the stationary phase using a suitable buffer solution (e.g., phosphate buffer at pH 6.1). The purpose of this step is to wash as much of the botulinum toxin complex as possible through the column while separating the botulinum toxin complex from other proteins and removing nucleic acids (RNA and DNA). In some embodiments, the salt concentration in this buffer solution is selected to maximize the amount of botulinum toxin or toxin complex flowing through the column while minimizing the amount of other proteins flowing through the column.
[0092] In some embodiments, the buffer solution contains sodium chloride (NaCl) at a concentration of not less than about 15 mM, not less than about 20 mM, not less than about 30 mM, not less than about 40 mM, not less than about 50 mM, not less than about 60 mM, not less than about 70 mM, not less than about 80 mM, not less than about 90 mM, not less than about 100 mM, not less than about 150 mM, not less than about 200 mM, not less than about 250 mM, not less than about 300 mM, not less than about 350 mM, not less than about 400 mM, not less than about 450 mM, or not less than about 500 mM (and ranges thereof). In some embodiments, the buffer solution comprises NaCl at a concentration of about 15 mM, about 20 mM, about 30 mM, about 40 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM, about 150 mM, about 200 mM, about 250 mM, about 300 mM, about 350 mM, about 400 mM, about 450 mM, or about 500 mM. In one embodiment, the buffer solution comprises NaCl at a concentration of about 150 mM.
[0093] In one particular embodiment, the first chromatography column can be operated in flow-through mode, wherein botulinum toxin and / or toxin complexes can flow through the column without adsorbing onto the stationary phase. In this configuration, dissociation of botulinum toxin or toxin complexes from the column is not required. Instead, botulinum toxin or toxin complexes can exit the column via a toxin-containing eluent 114, which can be collected and further purified in subsequent processing steps. In some embodiments, the collection of the toxin-containing eluent 114 is monitored by flow-through absorbance detection at 280 nm ("A280"), wherein the toxin-containing eluent 114 is collected during the appearance of the A280 peak. Second chromatography separation
[0094] Some embodiments of method 100 further include a second chromatographic separation step 116, wherein the toxin-containing eluent 114 can be purified to remove most impurities (e.g., other proteins) and produce a first toxin-containing eluent 118. The second chromatographic separation 116 may comprise any suitable chromatographic separation technique (e.g., ion exchange chromatography (including anion exchange chromatography or cation exchange chromatography), gel filtration chromatography, high-performance liquid chromatography, affinity chromatography, etc.). In a particular embodiment, the second chromatographic separation 116 comprises cation exchange chromatography (CIEX).
[0095] The second chromatographic separation 116 may involve contacting the botulinum toxin or toxin complex with a second chromatographic column, wherein a mobile phase containing the toxin-containing elution 114 travels through a second stationary phase. The second stationary phase may contain any suitable chromatographic matrix (e.g., an agarose bead-based medium, such as SP agarose FF (GE Healthcare)). In an embodiment, botulinum toxin molecules or toxin complexes may bind to the second stationary phase. In an embodiment, botulinum toxin or toxin complexes may bind to the second stationary phase, and the A280 of the solution washed through the column is monitored. In an embodiment, the column is washed with a suitable buffer solution (e.g., 50 mM sodium acetate, 0.2% polysorbate 20, pH 4.5) until the A280 has returned to baseline, indicating that all toxin-containing elution 118 has passed through the column, but the botulinum toxin and toxin complexes may remain bound to the second stationary phase.
[0096] In some embodiments, the second chromatographic separation 116 may further comprise washing the second chromatographic column with a washing buffer to remove any weakly bound proteins, while the botulinum toxin and toxin complex remain strongly bound to the second stationary phase. This washing step may use any suitable buffer solution (e.g., 50 mM sodium acetate, 0.2% polysorbate 20, pH 4.5, 210 mM NaCl). In some embodiments, this washing buffer may contain NaCl at concentrations of 250 mM or lower, 240 mM or lower, 230 mM or lower, 220 mM or lower, 210 mM or lower, 200 mM or lower, 190 mM or lower, 180 mM or lower, 170 mM or lower, 160 mM or lower, 150 mM or lower, 140 mM or lower, 130 mM or lower, 120 mM or lower, 110 mM or lower, or 100 mM or lower. In some embodiments, the washing buffer contains NaCl at concentrations of about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 210 mM, about 220 mM, about 230 mM, about 240 mM, or about 250 mM.
[0097] In some embodiments, the second chromatographic separation 116 may further include adjusting the toxin-containing lysate 114 for column chromatography (e.g., by dilution or buffer exchange) before contacting the toxin-containing lysate 114 with the second chromatographic column. For example, in some embodiments, the toxin-containing lysate 114 may be adjusted by dilution in an acetate-acetate buffer with a pH between about 3 and about 7, between about 3.5 and about 6, or between about 4 and about 5, with a preferred pH of about 4.5. In some embodiments, the toxin-containing lysate is adjusted in a buffer solution with a pH of about 3.5, about 3.6, about 3.7, about 3.8, about 3.9, about 4.0, about 4.1, about 4.2, about 4.3, about 4.4, about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, or about 5.5.
[0098] In some embodiments, the second chromatographic separation 116 may further include dissociation of botulinum toxin or toxin complex from the column to produce a first toxin-containing elution buffer 118. Dissociation may include washing the column with one or more buffer solutions (e.g., by changing pH or ionic strength) that promote the dissociation of the toxin (or toxin complex) from the stationary phase. This dissociation buffer may be any buffer suitable for promoting the dissociation of the toxin or toxin complex from the second stationary phase (e.g., 50 mM sodium acetate, 0.2% polysorbate 20, pH 4.5). For example, such a buffer solution may contain an acetate-acetate buffer with a pH between about 3 and about 7, between about 4 and about 6, between about 4 and about 5, or about 4.5. In some embodiments, the toxin-containing fraction is dissociated from the second chromatography column using a buffer solution with a pH of about 3.5, about 3.6, about 3.7, about 3.8, about 3.9, about 4.0, about 4.1, about 4.2, about 4.3, about 4.4, about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, or about 5.5.
[0099] In some embodiments, this dissociation buffer may contain a salt at a concentration sufficient to promote the dissociation of botulinum toxin or toxin complex from the second stationary phase. In embodiments, this dissociation buffer contains NaCl at concentrations of 230 mM or greater, 240 mM or greater, 250 mM or greater, 260 mM or greater, 270 mM or greater, 280 mM or greater, 290 mM or greater, 300 mM or greater, 350 mM or greater, or 400 mM or greater. In some embodiments, this dissociation buffer contains NaCl at a concentration of about 230 mM, about 240 mM, about 250 mM, about 260 mM, about 270 mM, about 280 mM, about 290 mM, about 300 mM, about 310 mM, about 320 mM, about 330 mM, about 340 mM, about 350 mM, about 360 mM, about 370 mM, about 380 mM, about 390 mM, or about 400 mM or any value between these values.
[0100] In an embodiment, botulinum toxin molecules or toxin complexes are dissociated from the column to produce a first toxin-containing precipitate 118, which can be collected and further purified in subsequent processing steps. In some embodiments, A280 is measured during dissociation from a second chromatography column to detect the presence of botulinum toxin molecules or toxin complexes dissociated from the column, and the A280 peak is collected as a single dissociated fraction to produce the first toxin-containing precipitate 118. Filtration 3
[0101] Some embodiments of the method further include a third filtration step 120 performed after the second chromatographic separation 116 and before the third chromatographic separation 124. In one embodiment, the third filtration 120 dissociates the NTH and / or NTNH proteins from the botulinum toxin complex. In one embodiment, the third filtration 120 includes a buffer exchange, which may increase the pH of the first toxin-containing elution buffer 118 (e.g., from about 4.5 to about 8.0). In one embodiment, the buffer exchange may reduce the salt concentration in the toxin-containing elution buffer 118 (e.g., from about 270 mM to about 50 mM). In one embodiment, the third filtration 120 may concentrate the toxin-containing elution buffer 118 (e.g., reduce its volume from about 300 mL to about 50-60 mL).
[0102] The third filtration 120 may comprise any suitable filtration technique (e.g., diafiltration, tangential flow microfiltration, tangential flow ultrafiltration, hollow fiber filtration, etc.). In one particular embodiment, the third filtration 120 may comprise ultrafiltration using a tangential flow filter (e.g., a hollow fiber filter) with a pore size suitable for retaining dissociated botulinum toxin molecules (150 kDa) and NTH and / or NTNH proteins. In some embodiments, the filter may have a pore size not greater than about 150 kDa, not greater than about 140 kDa, not greater than about 130 kDa, not greater than about 120 kDa, not greater than about 110 kDa, not greater than about 100 kDa, not greater than about 90 kDa, not greater than about 80 kDa, not greater than about 70 kDa, not greater than about 60 kDa, not greater than about 50 kDa, not greater than about 40 kDa, not greater than about 30 kDa, or not greater than about 20 kDa (or a range thereof). For example, the pore size of a tangential flow filter can be about 20 kDa, about 25 kDa, about 30 kDa, about 35 kDa, about 40 kDa, about 45 kDa, about 50 kDa, about 55 kDa, about 60 kDa, about 65 kDa, about 70 kDa, about 75 kDa, about 80 kDa, about 85 kDa, about 90 kDa, about 95 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, or about 150 kDa, or any value between these values. In one embodiment, the pore size of the filter is about 30 kDa.
[0103] In some embodiments, the toxin-containing elution buffer 118 may be concentrated by ultrafiltration, followed by washing with filtration relative to a buffer solution to dissociate NTH and / or NTNH proteins from the botulinum toxin complex. In a particular embodiment, botulinum toxin protein molecules and NTH and / or NTNH proteins may be retained in the retentate 121 (i.e., the toxin-containing retentate) while other filtration and chromatography medium residues are separated into the permeate.
[0104] The buffer solution used for the third filtration 120 may be any buffer solution suitable for dissociating the NTH and / or NTNH proteins in the toxin complex from the botulinum toxin molecules (e.g., Tris-HCl buffer). In some embodiments, the buffer solution used for the third filtration 120 may be the same buffer solution used to condition the third chromatography column (e.g., Tris-HCl buffer with a pH greater than 7, as discussed below).
[0105] In some embodiments, the pH of the buffer solution used for the third filtration 120 is suitable for dissociating NTH and / or NTNH proteins from botulinum toxin protein molecules. In some embodiments, the pH of the buffer solution is at least about 7, preferably between about 7 and about 10, preferably between about 7 and about 9, preferably between about 7.5 and about 8.5, and preferably about 8.0. In some embodiments, the pH of the buffer solution used for the third filtration 120 may be about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, about 8.0, about 8.1, about 8.2, about 8.3, about 8.4, about 8.5, about 8.6, about 8.7, about 8.8, about 8.9, about 9.0, about 9.5, or about 10.0. In one embodiment, the pH of the buffer solution for the third filtration 120 is about 8.0.
[0106] In some embodiments, the toxin-containing retentate 121 from the third filtration 120 can be collected and further purified in subsequent processing steps without precipitating botulinum toxin molecules or toxin complexes from solution at any point during the purification process. Advantageously, this increases the overall method yield and eliminates the need for reconstitution of the lyophilized drug at any point during the purification process or by the end user. Third Chromatographic Separation
[0107] Some embodiments of method 100 further include a third chromatographic separation 124 to separate and remove NTH and / or NTNH proteins that have dissociated from the toxin complex during the aforementioned third filtration 120, while retaining botulinum toxin protein molecules. The resulting second toxin-containing eluent 126 may contain free botulinum toxin protein molecules (approximately 150 kDa) and may be free of, substantially free of, or substantially free of the toxin complex. The third chromatographic separation 124 may include any suitable chromatographic separation technique (e.g., ion exchange chromatography (including anion exchange chromatography or cation exchange chromatography), gel filtration chromatography, high performance liquid chromatography, affinity chromatography, etc.). In a particular embodiment, the third chromatographic separation 124 may include anion exchange chromatography (AIEX).
[0108] The third chromatographic separation 124 may involve contacting the botulinum toxin or toxin complex in the toxin-containing retentate 121 from the third filtration 120 with a third chromatographic column, wherein a mobile phase containing the toxin-containing retentate 121 (and free botulinum toxin protein molecules therein) travels through a third stationary phase. The third stationary phase may contain any suitable chromatographic matrix (e.g., an agarose bead-based medium, such as Q agarose FF (GE Healthcare)).
[0109] In some embodiments, the third chromatographic separation 124 may further include adjusting the toxin-containing retentate 121 from the third filtration 120 for column chromatography (e.g., by dilution, buffer exchange, filtration, or a combination thereof). For example, the toxin-containing retentate 121 may be diluted in a buffer solution, such as a tris-HCl buffer with a pH greater than 7, preferably between 7 and 10, preferably between about 7 and about 9, preferably between about 7.5 and about 8.5, or preferably with a pH of about 8.0. In some embodiments, the pH of the buffer solution may be about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, about 8.0, about 8.1, about 8.2, about 8.3, about 8.4, about 8.5, about 8.6, about 8.7, about 8.8, about 8.9, about 9.0, about 9.5, or about 10.0.
[0110] In some embodiments, botulinum toxin protein molecules, toxin complexes, and NTH and / or NTNH proteins in the toxin-containing retentate 121 can be adsorbed onto the third stationary phase. In some embodiments, the toxin-containing retentate 121 is loaded onto a third chromatography column and washed with a washing buffer to remove non-toxin impurities not bound to the third stationary phase. The washing buffer can be any suitable buffer solution (e.g., 20 mM tris / HCl, 50 mM NaCl, 0.2% polysorbate 20, pH 8.0), and the A280 of the solution passing through the column can be monitored until the A280 reaches the baseline value, indicating that all unbound material has flowed through the third chromatography column.
[0111] The third chromatography separation 124 may further include dissociating the botulinum toxin protein bound to the third stationary phase to produce a second toxin-containing elution solution 126. Dissociation may include washing the column with one or more buffer solutions to allow the botulinum toxin protein molecules to desorb from the stationary phase using any suitable protein-compatible buffer solution (e.g., by changing pH, ionic strength, etc.). For example, a tris-HCl buffer solution with a pH greater than 7, preferably between 7 and 10, preferably between about 7 and about 9, preferably between about 7.5 and about 8.5, or preferably about 8.0, may be used to dissociate the botulinum toxin molecules from the third stationary phase. In some embodiments, the pH of the buffer solution is about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, about 8.0, about 8.1, about 8.2, about 8.3, about 8.4, or about 8.5.
[0112] In some embodiments, the buffer solution for dissociating botulinum toxin molecules from the third chromatography column may contain a salt (e.g., NaCl). In some embodiments, the buffer solution for dissociating botulinum toxin molecules from the third chromatography column contains NaCl at a concentration suitable for promoting the desorption of botulinum toxin molecules from the third stationary phase. In embodiments, this dissociation buffer may contain NaCl at a concentration between about 25 mM and about 250 mM, preferably between about 50 mM and about 200 mM, preferably between about 100 mM and about 150 mM, and preferably about 120 mM. In some embodiments, the dissociation buffer for dissociating botulinum toxin molecules from a third chromatography column contains NaCl at concentrations of about 50 mM, about 60 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM, about 110 mM, about 115 mM, about 120 mM, about 125 mM, about 130 mM, about 135 mM, about 140 mM, about 145 mM, about 150 mM, about 155 mM, about 160 mM, about 165 mM, about 170 mM, about 175 mM, about 180 mM, about 185 mM, about 190 mM, about 195 mM, about 200 mM, about 210 mM, about 220 mM, about 230 mM, about 240 mM, or about 250 mM. In one embodiment, the buffer solution used to dissociate botulinum toxin molecules from the third chromatography column contains about 120 mM or about 150 mM NaCl.
[0113] In some embodiments, the buffer solution for dissociating botulinum toxin molecules from the third chromatography column further comprises a surfactant (e.g., polysorbate 20). In some embodiments, the buffer solution for dissociating botulinum toxin molecules from the third chromatography column comprises a surfactant at a concentration of about 0.05 vol.-% to about 1.0 vol.-%, preferably about 0.10 vol.-% to about 0.5 vol.-%, preferably about 0.15 vol.-% to about 0.25 vol.-%, preferably about 0.20 vol.-%. In some embodiments, the buffer solution for dissociating botulinum toxin molecules from the third chromatography column contains a surfactant at a concentration of about 0.05 vol.-%, about 0.10 vol.-%, about 0.15 vol.-%, about 0.20 vol.-%, about 0.25 vol.-%, about 0.30 vol.-%, about 0.35 vol.-%, about 0.40 vol.-%, about 0.45 vol.-%, about 0.50 vol.-%, about 0.55 vol.-%, about 0.60 vol.-%, about 0.65 vol.-%, about 0.70 vol.-%, about 0.75 vol.-%, about 0.80 vol.-%, about 0.85 vol.-%, about 0.90 vol.-%, about 0.95 vol.-%, or about 1.0 vol.-%. In one embodiment, the buffer solution used for dissociating botulinum toxin molecules from the third chromatography column contains polysorbate 20 at a concentration of about 0.20 vol.%.
[0114] In a particular embodiment, the second toxin-containing lysate 126 is collected as is from its dissociation from the column and further purified in subsequent method steps without precipitating or lyophilizing the botulinum toxin protein. In one embodiment, the second toxin-containing lysate 126 is injected directly into a fourth chromatography column for final purification (i.e., removal of high molecular weight contaminants, including target protein aggregates, and low molecular weight contaminants, including target protein fragments, and other impurities that may not have been removed in the aforementioned purification steps). Fourth chromatography separation
[0115] Some embodiments of method 100 further include a final purification step, which uses a fourth chromatographic separation 128 to remove aggregates and / or protein impurities from the second toxin-containing eluent 126, producing a third toxin-containing eluent 130. The fourth chromatographic separation 128 may include any suitable chromatographic separation technique (e.g., ion exchange chromatography (including anion exchange chromatography or cation exchange chromatography), gel filtration chromatography, high performance liquid chromatography, affinity chromatography, etc.). For example, in one embodiment, the fourth chromatographic separation 128 may include gel filtration chromatography.
[0116] The fourth chromatographic separation 128 can use any suitable protein-compatible chromatographic matrix capable of separating pure botulinum toxin protein molecules from aggregated botulinum toxin and other protein impurities. For example, the fourth chromatographic separation 128 can use Superdex 200 chromatography medium (GE Healthcare).
[0117] The fourth chromatographic separation 128 may further include conditioning the second toxin-containing elution buffer 126 for column chromatography (e.g., by dilution, buffer exchange, filtration, or a combination thereof). Alternatively, in a particular embodiment, the second toxin-containing elution buffer 126 from the third chromatographic separation 124 may be injected directly onto the fourth chromatographic column without further conditioning. In this configuration, the third and fourth chromatographic columns may be interconnected to allow direct loading of the second toxin-containing elution buffer 126.
[0118] The fourth chromatographic separation 128 may further comprise washing botulinum toxin molecules through the stationary phase using a washing solution or buffer to provide a third toxin-containing elution buffer 130. The buffer solution may be any suitable protein-compatible buffer. In one particular embodiment, the buffer solution may be an acetate-acetate buffer solution with a pH less than about 7, preferably between about 5 and about 7, preferably between about 6 and about 7, and preferably between about 6.6 and about 6.9. In some embodiments, the pH of this buffer solution may be about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, or about 7.0.
[0119] In some embodiments, the buffer solution used to wash botulinum toxin molecules through the stationary phase in the fourth chromatography column further comprises a salt (e.g., NaCl). In some embodiments, this washing buffer solution contains NaCl at a concentration of about 100 mM to about 1 M, preferably about 200 mM to about 600 mM, more preferably about 300 mM to about 500 mM, and most preferably about 400 mM. In some embodiments, the buffer solution contains NaCl at concentrations of about 100 mM, about 150 mM, about 200 mM, about 250 mM, about 300 mM, about 310 mM, about 320 mM, about 330 mM, about 340 mM, about 350 mM, about 360 mM, about 370 mM, about 380 mM, about 390 mM, about 400 mM, about 410 mM, about 420 mM, about 430 mM, about 440 mM, about 450 mM, about 500 mM, about 550 mM, about 600 mM, about 650 mM, about 700 mM, about 750 mM, about 800 mM, about 850 mM, about 900 mM, about 950 mM, or about 1 M. In one embodiment, the buffer solution used to wash botulinum toxin molecules through the stationary phase in the fourth chromatography column contains about 350 mM NaCl or about 370 mM NaCl.
[0120] In some embodiments, the buffer solution used to wash botulinum toxin molecules through the stationary phase in the fourth chromatography column further comprises a surfactant (e.g., polysorbate 20). In some embodiments, this buffer solution contains a surfactant at a concentration of about 0.05 vol.-% to about 1.0 vol.-%, preferably about 0.10 vol.-% to about 0.5 vol.-%, preferably about 0.15 vol.-% to about 0.25 vol.-%, preferably about 0.20 vol.-%. In some embodiments, this buffer solution contains a surfactant at a concentration of about 0.05 vol.-%, about 0.10 vol.-%, about 0.15 vol.-%, about 0.20 vol.-%, about 0.25 vol.-%, about 0.30 vol.-%, about 0.35 vol.-%, about 0.40 vol.-%, about 0.45 vol.-%, about 0.50 vol.-%, about 0.55 vol.-%, about 0.60 vol.-%, about 0.65 vol.-%, about 0.70 vol.-%, about 0.75 vol.-%, about 0.80 vol.-%, about 0.85 vol.-%, about 0.90 vol.-%, about 0.95 vol.-%, or about 1.0 vol.-%. In one embodiment, the buffer solution used to wash botulinum toxin molecules through the stationary phase in the fourth chromatography column contains polysorbate 20 at a concentration of about 0.20 vol.-%.
[0121] In some embodiments, the presence of free botulinum toxin molecules in the solution passing through the column is monitored according to A280. In one embodiment, the A280 peak (indicating the presence of free botulinum toxin molecules) is collected as a single elution fraction to produce a third toxin-containing elution solution 130.
[0122] In some embodiments, the third toxin-containing eluent 130 may be collected undiluted from the fourth chromatography column and diluted or further purified in subsequent method steps without precipitating or lyophilizing the botulinum toxin protein. In some embodiments, the third toxin-containing eluent 130 may be stored at approximately 2-8°C until post-purification processing. In some embodiments, the third toxin-containing eluent 130 may be diluted, filtered, and dispensed to provide the product toxin solution 134. Dilution, filtration, and dispensing
[0123] In some embodiments, method 100 further includes diluting, filtering, and dispensing 132 a third toxin-containing eluent 130 to provide a product toxin solution 134. In some embodiments, the third toxin-containing eluent 130 may be diluted to a final concentration using any suitable buffer solution. In some embodiments, the composition of the diluent buffer solution is approximately the same as that of the wash buffer used in the fourth chromatographic separation 128. For example, the diluent buffer solution may contain an acetate-acetate buffer solution with a pH less than about 7, preferably between about 5 and about 7, preferably between about 6 and about 7, and preferably between about 6.6 and about 6.9. In some embodiments, the pH of this buffer solution is about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, or about 7.0.
[0124] Method 100 may further include filtering a third toxin-containing eluent 130 (or a diluted form thereof) to reduce bioburden and provide a product toxin solution 134. Filtering the third toxin-containing eluent 130 may incorporate any suitable filtration technique (e.g., diafiltration, tangential flow microfiltration, tangential flow ultrafiltration, hollow fiber filtration, etc.). In some embodiments, the filter may have a pore size between 0.1 µm and 10 µm (e.g., approximately 0.2 µm).
[0125] The product toxin solution 134 can be dispensed into containers (e.g., cryogenic vials) that can be transported and stored while maintaining the efficacy of the botulinum toxin protein therein. For example, the product toxin solution 134 can be dispensed into pre-frozen storage containers (e.g., vials contained in pre-frozen aluminum blocks), transported, and / or stored.
[0126] In some embodiments, dispensing the product toxin solution 134 may include pumping the product toxin solution from a sterile container (e.g., a disposable sterile bag) to a primary storage container (e.g., a cryogenic vial). In some embodiments, the primary storage container may be pre-frozen and maintained at an appropriate temperature (e.g., equal to or below 0°C), for example, by storing, transporting, and freezing the primary storage container in a pre-frozen aluminum block. This maintains the product toxin solution 134 at a temperature that stabilizes the botulinum toxin molecules and preserves their neurotoxicity. It also eliminates the need for lyophilizing the product toxin solution 134. The product toxin solution 134 may also be stored at a temperature equal to or below approximately 0°C, preferably at approximately -70°C or lower. Method Yield
[0127] The overall method yield and the yield of each step can be calculated to evaluate the purification method. The yield can be calculated using the toxin concentration obtained in each dissociated fraction. The yield of each method step (i.e., "method step yield") can be calculated according to the following formula: (Equation 1) where C is the toxin concentration, V is the volume, the subscript dissociated fraction indicates the toxin concentration or volume obtained from the current processing step, and the subscript of the previous dissociated fraction indicates the toxin concentration or volume obtained from the previous processing step. For example, if the method step produces 1.0 µg / mL toxin in a 1000 mL volume, and the previous method step produces 0.5 µg / mL toxin in a 4000 mL volume, then the method step yield will be 50%. ([1.0 µg / mL × 1000 mL] / [0.5 µg / mL × 4000 mL]) × 100 = 50%.
[0128] The total yield can be calculated using the following formula: (Equation 2) where C is the concentration, V is the volume, the subscript DS represents the active pharmaceutical ingredient (i.e., the product toxin solution), and the subscript KS represents the culture at collection, where cells are removed by filtration through a 0.2 µm filter. For example, if DS contains 50 µg / mL in 100 mL and the culture at collection contains 5 µg / mL toxin in 5000 mL, then the total yield will be 20%. ([50 µg / mL × 100 mL] / [5 µg / mL × 5000 mL]) × 100 = 20%.
[0129] In some embodiments, the total yield is at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, or any range or value between these values. In some embodiments, the total yield is about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40%, or any value between these values.
[0130] In one embodiment, the purity of the active pharmaceutical ingredient (API) can be determined using SDS-PAGE and / or HPLC-SEC. In one embodiment, the API obtained according to the method of the present invention has a purity of at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% (and ranges therebetween). In one embodiment, the API may have a purity of about 96.0%, about 96.5%, about 97.0%, about 97.5%, about 98.0%, about 98.5%, about 99.0%, about 99.5%, or about 100.0%, or any value therebetween. Example 1: Four-column chromatography method for purifying botulinum toxin
[0131] For example, one embodiment of the method may be implemented according to the following description, wherein botulinum toxin A1 (approximately 150 kDa) is recovered from a fermentation medium containing Clostridium botulinum cells and botulinum toxin A1 protein molecules and toxin complexes, and which is substantially free of, substantially free of, or substantially free of animal products. Such an APF fermentation medium is described in U.S. Provisional Patent Application No. 62 / 951,549, which is also filed. The botulinum toxin therein is filtered and purified according to the method steps described in more detail below to produce a product toxin solution containing botulinum toxin protein molecules and free of, substantially free of, or substantially free of toxin complexes, without the use of any precipitation or lyophilization steps. Buffer Preparation
[0132] As shown in Table 1, various different buffer solutions can be used in this method embodiment. In one embodiment, the buffer solution is passed through a 0.2 µm filter (to reduce bioload) into a disposable sterile bag. The filter used is then interrupted, and the bag containing the buffer solution is stored at room temperature until use.
[0133] Table 1. Buffer solutions used in the BoNT / A1 purification method The buffer solution used in the BoNT / A1 purification method Column Chromatography Buffer solution used First chromatography separation Q Agarose FF 1. 20 mM sodium phosphate, 1 M NaCl, pH 6.1 2. 20 mM sodium phosphate, 150 mM NaCl, pH 6.1 3. 20 mM sodium phosphate, 50 mM NaCl, pH 6.1 4. 20 mM sodium phosphate, 150 mM NaCl, pH 6.1 Second chromatography separation SP agarose FF 5. 50 mM sodium acetate, 1 M NaCl, 0.2% polysorbate 20, pH 4.5 6. 50 mM sodium acetate, 0.2% polysorbate 20, pH 4.5 7. 100 mM sodium acetate, 0.4% polysorbate 20, pH 4.5 8. 50 mM sodium acetate, 210 mM NaCl, 0.2% polysorbate 20, pH 4.5 9. 50 mM sodium acetate, 270 mM NaCl, 0.2% polysorbate 20, pH 4.5 Third chromatography separation Q Agarose FF 10. 20 mM tris-HCl, * 50 mM NaCl, pH 8.0 11. 20 mM tris-HCl, 1 M NaCl, 0.2% polysorbate 20, pH 8.0 12. 20 mM tris-HCl, 50 mM NaCl, 0.2% polysorbate 20, pH 8.0 13. 20 mM tris-HCl, 50 mM NaCl, 0.2% polysorbate 20, pH 8.0 14. 20 mM tris-HCl, 120 mM NaCl, 0.2% polysorbate 20, pH 8.0 Fourth chromatography separation Superdex 200 15. 50 mM sodium acetate, 370 mM NaCl, 0.2% polysorbate 20, 13 mM Na₂HPO₄, 17 mM NaOH, pH 6.6-6.9 16. 50 mM sodium acetate, 370 mM NaCl, 0.2% polysorbate 20, 13 mM Na₂HPO₄, 17 mM NaOH, pH 6.6-6.9 Post-purification Final dilution 17. 50 mM sodium acetate, 370 mM NaCl, 0.2% polysorbate 20, 13 mM Na₂HPO₄, 17 mM NaOH, pH 6.6-6.9 * Abbreviation: Tris-HCl = Tris(hydroxymethyl)aminomethane hydrochloride
[0134] In Table 1, buffers 1 and 2 are used to equilibrate the first chromatography column; buffer 3 is used to prepare the clarified culture for column chromatography; buffer 4 is used to wash the botulinum toxin complex flowing through the first column in a flow-through mode; buffers 5 and 6 are used to equilibrate the second chromatography column; buffer 7 is used to prepare the toxin-containing lysate from the first chromatography for the second chromatography; buffer 8 is used to wash away most impurities (e.g., proteins) through the second chromatography column; buffer 9 is used to dissociate the bound botulinum toxin complex from the second chromatography column; and buffer 10 is used to bind NTH and / or NTNH proteins to botulinum toxin. Botulinum toxin protein molecules are separated (i.e., the first toxin-containing elution buffer from the second chromatography is adjusted for the third chromatography); buffers 11 and 12 are used to equilibrate the third chromatography column; buffer 13 is used to wash away impurities in the third chromatography column; buffer 14 is used to dissociate the bound botulinum toxin protein molecules from the third chromatography column; buffer 15 is used to equilibrate the fourth chromatography column; buffer 16 is used to wash the botulinum toxin molecules through the fourth chromatography column; and buffer 17 is used to dilute the toxin-containing elution buffer from the fourth chromatography to its final concentration, which is then dispensed into the main storage container to obtain the product toxin solution. Filtration.
[0135] The Clostridium botulinum fermentation medium was obtained from the APF production method described in U.S. Provisional Patent Application No. 62 / 951,549, which is also pending. After collection, the culture (approximately 5 L) was diluted directly with approximately 280 mL of a pH-adjusting buffer solution (1 M sodium acetate, 4 M NaCl, pH 5.5) and then filtered. The diluted solution was filtered by microfiltration (“Filter 1”) using a 0.2 µm hollow fiber filter and by tangential flow filtration to separate spores and intact and dissolved Clostridium botulinum cells, providing a clear culture. The clear culture was sampled for in-process control based on the absence of Clostridium botulinum. The clear culture was then purified by tangential flow ultrafiltration (“Filter 2”) using a 50 kDa hollow fiber filter to remove fermentation medium residues (e.g., proteins, carbohydrates, etc.). The clarified culture was then subjected to buffer exchange in sodium phosphate buffer (pH approximately 6.1) to prepare the clarified culture for column chromatography. This filtration method, and other suitable protein filtration methods, are known in this technique. See, for example, Munir Cheryan, Ultrafiltration and Microfiltration Handbook (2nd edition, 1998). Purification
[0136] A four-column chromatography method has been developed for the purification of BoNT / A1 protein molecules (approximately 150 kDa) without the use of any precipitation, lyophilization, or centrifugation steps. This method provides a product toxin solution that is free of, substantially free of, or substantially free of botulinum toxin complexes and / or animal products. This increases yield and eliminates end-user errors associated with the reconstitution process, which are known to reduce the efficacy of botulinum toxin pharmaceutical compositions.
[0137] This method utilizes a botulinum toxin complex in the initial step to protect the toxin while removing proteases and most other contaminating proteins. The first chromatographic step is anion exchange chromatography, which removes most of the nucleic acids in the culture medium at the time of collection, which would otherwise interfere with downstream chromatographic steps. This inhibits the denaturation of botulinum toxin molecules during the purification process. The method then separates the botulinum toxin protein molecules from their associated NTH and / or NTNH proteins to provide a product toxin solution containing pure botulinum toxin molecules (approximately 150 kDa) and free from, substantially free from, or substantially free from the botulinum toxin complex.
[0138] Furthermore, all chromatographic steps used in this method are designed to be performed on disposable chromatographic columns, which can be discarded after a single purification process. This eliminates the costly and time-consuming column regeneration steps encountered in reusable chromatographic systems. The entire method is performed using a closed system, utilizing disposable bags, tubes, filters, and chromatographic columns. Additionally, open operation steps are avoided because the process fluid is preferably maintained within the bag, tube, filter, or column, thereby preventing contamination of the product toxin solution and protecting operators from toxin exposure.
[0139] Table 2 summarizes the four-column chromatography purification method of BoNT / A1 according to the present invention. The method includes the following steps: (1) using sodium phosphate buffer (pH 6.1), the clarified culture is directly injected into a Q agarose FF column (2.5 L packed in the column, 80 mm in diameter and 500 mm in height) in flow-through mode to separate the botulinum toxin complex from the nucleic acid. In this step, the botulinum toxin complex is not bound to the stationary phase, but instead flows through the column as a toxin-containing lysate. (2) The toxin-containing lysate from the Q agarose FF column (100 mL packed in the column, 50 mm in diameter and 50 mm in height) is adjusted with sodium acetate buffer (pH 4.5) and passed through the SP agarose FF column using sodium acetate buffer (pH 4.5). In this step, the botulinum toxin complex is adsorbed onto the stationary phase, while most impurities (e.g., other proteins) are washed off and pass through the column. The toxin complex bound to the column was dissociated using a sodium acetate buffer containing NaCl (pH 4.5) and collected as a first toxin-containing elution. (3) The first toxin-containing elution was filtered to remove fermentation medium residue and conditioned with a suitable buffer solution. This conditioning was achieved by tangential flow ultrafiltration ("filtration 3") using a 30 kDa filter for buffer exchange (tris-HCl buffer, pH 8.0) to dissociate botulinum toxin molecules from NTH and / or NTNH proteins in the toxin complex. The retentate was then passed through a Q agarose FF column (2 mL, 5 mm in diameter and 100 mm in height) to separate the free botulinum toxin protein from the NTH and / or NTNH protein. In this step, botulinum toxin molecules adsorbed onto the stationary phase, while NTH and / or NTNH proteins (and most other impurities) were washed down to some extent through the column (but mainly adsorbed onto the stationary phase, even more strongly than botulinum toxin molecules). The botulinum toxin protein was dissociated using a tris-HCl buffer (pH 8.0) containing NaCl and collected as a second toxin-containing elution. (4) The second toxin-containing elution was directly injected into a Superdex 200 gel filter column (320 mL, 25 mm in diameter and 600 mm in height) for final purification (i.e., removal of aggregates). In this step, the column was washed with a buffer containing 50 mM sodium acetate, 370 mM NaCl, 0.2% polysorbate 20, 13 mM Na2HPO4 and 17 mM NaOH (pH 6.6-6.9), and the purified botulinum toxin protein was collected as a third toxin-containing elution.
[0140] Table 2. Overview of column chromatography steps in the BoNT / A1 purification method Overview of column chromatography procedures tubular technology stationary phase Purpose 1 AIEX Q Agarose FF Toxins flow through; nucleic acids bind to the column. 2 CIEX SP agarose FF Separate most impurities (such as proteins). 3 AEIX Q Agarose FF Purification of the complex protein (i.e., NTH and NTNH) 4 Gel filtration Superdex 200 Final purification; removal of aggregates; buffer exchange
[0141] Each column chromatography step described above may include an in-situ cleaning procedure and other column preparation steps prior to performing chromatographic separation. Column preparation and operating procedures are well known in this art. See also, for example, Ozutsumi et al., 49 APPL. ENVTL. MICROBIOL. 939 (1985); GE Healthcare, Strategies for Protein Purification Handbook (2010); Schmidt et al., 156 ANAL. Biochem. 213 (1986); Simpson et al., 165 Methods Enzymol. 76 (1988); Zhou et al., 34 Biochem. 15175 (1995); Kannan et al., 15 Mov. DISORD. 20 (2000); Wang Yc, DERMATOL. LAS FACIAL COSMET. SURG. 58 (2002); Johnson et al., 32 PROTEIN EXPR. & PURIF. 1 (2003); US 2003 / 0008367 A1. Dilution / Filtration / Dispensing
[0142] The purified botulinum toxin protein was diluted to its final concentration in a suitable buffer solution (e.g., 50 mM sodium acetate, 0.2% polysorbate 20, 370 mM NaCl, 13 mM sodium phosphate, 17 mM NaOH) and gently mixed on a platform shaker for approximately 30 minutes. The diluted product was filtered through a 0.2 µm filter into a disposable sterile bag and dispensed into 1.8 mL vials using a dispensing pump and syringe at 0.4 mL aliquots. The samples were then rapidly frozen using pre-frozen aluminum blocks and stored at <-70°C. The final solution prepared according to this method for storage is referred to hereinafter as the "active drug substance" (or "DS").
[0143] Three different batches of active pharmaceutical ingredients (APIs) were prepared according to the steps outlined above: #16852, #17043, and #19139. The appearance, potency, specific activity, and total protein concentration of the DS batches were then tested, as described in the examples below.
[0144] Example 2: Appearance Test
[0145] Clarity and color are tested to verify that the active pharmaceutical ingredient (API) is transparent and colorless, as the emulsification of the solution can indicate protein aggregation or precipitation. This method is a visual method based on European Pharmacopoeia (Ph. Eur.) 2.2.1 entitled "Clarity and Degree of Opalescence of Liquids" and European Pharmacopoeia 2.2.2 entitled "Degree of Coloration of Liquids," but with the variation of using vials and volumes for the API instead of the containers and volumes specified in the pharmacopoeia methods. Water is used as a reference solution.
[0146] By this method, all batches of the active pharmaceutical ingredient prepared according to Example 1 were clear and colorless solutions, indicating that no detectable aggregation or precipitation of botulinum toxin protein molecules occurred. Example 3: Efficacy
[0147] The potency of the purified active pharmaceutical ingredient obtained from Example 1 was determined using mouse LD50 analysis. This was an absolute analysis to quantitatively measure the potency within the tested sample. Gelatin-phosphate buffer was used as a diluent, and 11 dose groups centered on the target LD50 value were established. The dose groups with potency between 3.0 and 0.4 units per dose were equally spaced in a logarithmic range of approximately 0.0899. The number of deaths was recorded at 72 hours post-injection, and the LD50 was calculated using the Spearman-Karber method. In terms of mortality, the Spearman-Karber calculation was used as a mathematical method to determine the midpoint (LD50) of the logarithmic dilution curve. The potency of the purified active pharmaceutical ingredient is expressed as LD50 units / mL. See, for example, MA Ramakrishnan, Determination of 50% Endpoint Titer Using a Simple Formula, 5 WORLD J. VIROL. 85-86 (2016); see also G. Kärber, 162 PATHOL. U PHARMAKOL. 480-83 (131); C. Spearman, The Method of “Right and Wrong Cases” (Constant Stimuli) Without Gauss's Formula, 2 BR. J. PSYCHOL. 227-42 (1908).
[0148] Purified active pharmaceutical ingredient batches #16852, #17043, and #19139 showed potency values of 11 × 10⁶ LD₅₀ units / mL, 23 × 10⁶ LD₅₀ units / mL, and 19 × 10⁶ LD₅₀ units / mL, respectively. The combination of these potency values and the resulting DS volume confirms that the yield of this method is sufficient for high drug doses produced from DS batches, as required for the production of commercially available DS. Example 4: Total Protein Concentration
[0149] The total protein concentration of the active pharmaceutical ingredient prepared according to Example 1 was determined by the quinolinic acid (BCA) method, as it has sufficient sensitivity to determine the protein concentration of a typical batch of the active pharmaceutical ingredient prepared according to Example 1. See European Pharmacopoeia 2.5.33 Method 4; also see USP <507> Method II.
[0150] The microBCA protein analysis kit is used to determine total protein concentration, and a standard curve of bovine serum albumin is used to calculate protein concentration based on measured absorbance. Results are reported as the average of measurements from two replicates.
[0151] For the purified active pharmaceutical ingredient batches #16852, #17043, and #19139, the total protein concentrations were determined to be 59.4 µg / mL, 107.0 µg / mL, and 91.4 µg / mL, respectively. These high protein concentration values obtained for the DS batches are sufficient to ensure the accuracy and precision of the analytical methods used for release and characterization. Example 5: Specific Activity
[0152] For the active pharmaceutical ingredient (API) produced according to Example 1, the specific activity was calculated using the API potency value (units / mL) obtained by LD50 analysis (Example 3) and the total protein concentration of the API (Example 4) (mg / mL). The specific activity was calculated according to the following formula: (Equation 3)
[0153] For the purified active pharmaceutical ingredient batches #16852, #17043, and #19139, the specific activities were determined to be 1.9 × 10⁸ U / mg, 2.2 × 10⁸ U / mg, and 2.1 × 10⁸ U / mg, respectively. This confirms the high purity of DS, indicating that this method is suitable for the commercial production of highly purified and fully active non-complex botulinum toxin. Example 6: Protein-related impurities
[0154] The method for determining protein-related impurities in the drug substance prepared according to Example 1 is based on the principle described in the European Pharmacopoeia 2.2.31 Electrophoresis entitled "Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) - Uniform Percentage Gels." In this method, SDS-PAGE is used in combination with colloidal Coomassie Blue staining. A standard curve is prepared by diluting the sample; non-reduced and reduced samples are analyzed. Impurities are quantified by density determination, by correlating the band intensity of the impurity bands with the standard curve. The impurity results are expressed as a percentage of the total protein content loaded on the gel.
[0155] Figure 2 shows the purity analysis results of DS batch #17043 prepared according to Example 1. These results were obtained using SDS-PAGE and colloidal Coumarin blue staining. Lanes from left to right: 1-5: Standard curves of non-reducing samples of batch #17043 (1.2-4.0 µg / mL); 6-7: Replicas 1 and 2 of non-reducing batch #17043 (140 µg / mL); 8: Molecular weight markers; and 9-10: Replicas 1 and 2 of reducing batch #17043 (140 µg / mL). For all three drug substance batches prepared according to Example 1, protein-related impurities were <6.0%, and batch #16852, in particular, showed no detectable impurities. Example 7: Residual Nucleic Acids
[0156] Limit tests were performed on residual nucleic acids to detect RNA and / or DNA in the active pharmaceutical ingredient prepared according to Example 1. This method used a commercially available RiboGreen RNA quantification kit. RiboGreen binds to nucleic acids, and the resulting fluorescent signal is proportional to the amount of nucleic acid in the sample. Since DNA produces a higher signal when it binds to RiboGreen than RNA, estimating the nucleic acid content in DNA-containing samples using RNA-containing standards would be overstated, resulting in a reported nucleic acid value representing the maximum amount of nucleic acid in the sample.
[0157] The purified active pharmaceutical ingredient batches #16852, #17043, and #19139 were compared with a reference standard curve, where the lowest standard sample had RNA of 0.15 μg / mL. All three batches showed sample fluorescence below the standard corresponding to ≤0.15 μg / mL residual nucleic acid (data not shown). Example 8: Protein Mapping
[0158] The method used for protein mapping is based on the principle described in the European Pharmacopoeia 2.2.31 electrophoresis, entitled "Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) - Uniform Percentage Gels." Purified drug substance batches #16852, #17043, and #19139 were analyzed on 4-12% Bis-Tris gels to separate constitutive proteins and stained with silver staining agents (SilverQuest staining kit). Figure 3 shows the SDS-PAGE results comparing reducing (lanes 6-9) and non-reducing (lanes 2-5) drug substance samples with molecular weight markers (1 and 10). Lanes 3 and 7 correspond to batch #16852; lanes 4 and 8 correspond to batch #17043; and lanes 5 and 9 correspond to batch #19139. (Lane 2 and 6 show the results of the drug substance batch (#1014997) prepared using slightly different process parameters (e.g., the buffer pH in the first chromatographic separation was slightly higher) according to the four-column chromatography method).
[0159] Purified API batches #1014997, #16852, #17043, and #19139 showed similar protein spectra with a strong band of approximately 150 kDa (lanes 2, 3, 4, and 5, respectively), indicating that the major protein component is free BoNT / A. The reduced samples in lanes 6, 7, 8, and 9 showed two major protein components: approximately 100 kDa and 150 kDa, corresponding to the heavy and light chains of BoNT / A, respectively. Example 9: Molecular Weight Distribution of API
[0160] Size exclusion chromatography (SEC) was used to monitor the molecular weight size distribution of drug substance components. This method analyzes the major components in a sample, including product toxins and any high and low molecular weight substances (HMW and LMW, respectively) that may be related to the method or product. UPLC® SEC columns were used for separation. The mobile phase was buffer 17 (Table 1 above) supplemented with 0.4 M L-arginine at a pH between 6.6 and 6.9. L-arginine was added to buffer 17 to minimize secondary interactions between the separated proteins and the column matrix, filter, and other contacting components of the chromatography system. Double-replicated samples (from one drug substance vial) were analyzed at a flow rate of 0.25 mL / min without any pretreatment or dilution. Detection was performed at 280 nm. The resulting chromatograms were integrated, and the average area percentage (area%) of the major component in each drug substance batch was reported.
[0161] Figure 4 shows the molecular weight distribution of DS batch #17043 prepared according to Example 1. The main peak corresponds to the free product toxin molecules. The purified active pharmaceutical ingredient batches #16852, #17043 and #19139 all show at least 96% of the major component (BoNT / A). This data confirms the high purity level of botulinum toxin in the product toxin solution prepared according to the present invention. Example 10: Method Steps Yield
[0162] The yield of BoNT / A in each step of the purification process was determined as a stability indicator. To calculate the yield of each step, the volume of each dissolved fraction was measured. To determine the BoNT / A concentration in each dissolved fraction, a BoNT / A-specific ELISA was used.
[0163] The ELISA protocol is an indirect sandwich ELISA, based on the principles and general methods described in USP <1103>, "Immunoassay Methods - Enzyme-Linked Immunosorbent Assay". The ELISA method is based on the immune binding and detection of BoNT / A using two different types of BoNT / A-specific polyclonal antibodies.
[0164] A series of protein standard dilutions based on commercially available BoNT / A toxin were prepared by diluting BoNT / A to a concentration range of 3-28 ng / mL in PBS-Tween solution (0.05% Tween-20). Samples diluted to the protein standard dilution range in PBS-Tween were added in triplicate to the wells of a microculture disc coated with multiple anti-BoNT / A antibodies. Incubation induced antibody recognition and BoNT / A antigen binding to the wells. An automated washing step using PBS-Tween solution was performed after each incubation.
[0165] Initial detection was performed based on the binding of another type of multi-anti-BoNT / A antibody, inducing the formation of a sandwich complex. A secondary antibody conjugated with horseradish peroxidase (HRP) was then added. Its binding to the primary antibody allowed for the detection of BoNT / A within the sandwich complex. 3,3',5,5'- Tetramethylbenzidine (TMB) acceptor was then added to the sample wells. HRP converted the TMB acceptor, producing a blue reaction product. A stop solution was added to prevent TMB conversion, and the initial remaining TMB color turned yellow. The absorbance of each well in the microculture disc at 450 nm was measured using a disc reader; the measured absorbance was proportional to the amount of BoNT / A in the well. The sample absorbance value was calculated by comparison with a standard curve based on absorbance values obtained from a BoNT / A standard dilution. The results were reported as average values (μg / mL). The yield of the method step was then calculated according to Equation 1 above.
[0166] Figure 5 shows the average method step yields for each step in the purification process for batches #16852, #17043, and #19139. The bars marked "DS" show the combined yields of the last two chromatographic steps when they are interconnected, without sampling in between. Data shows that method step yields range from approximately 50% to approximately 100%. Example 11: Cumulative Method Step Yields
[0167] The cumulative method step yield for each individual method step is calculated using the following formula: (Equation 4) where C is the toxin concentration, V is the volume, the subscript "dissolution fraction" indicates the toxin concentration or volume from the current processing step, and the subscript KS indicates the culture at collection, wherein cells are removed by filtration through a 0.2 µm filter. The cumulative method step yield of the culture at collection (KS) is set to 100%.
[0168] Figure 6 shows the average cumulative method step yield of each step in the purification process for purified drug substance batches #16852, #17043, and #19139. The bars marked "DS" show the combined yield of the two final chromatographic steps when they are interconnected without sampling in between. Example 12: Overall Yield
[0169] The total yield of BoNT / A in the product toxin solution (or "DS") compared to the culture at collection ("KS") was determined as an indicator of the overall stability of the purification method. To calculate the method yield, the KS and DS solutions were weighed to determine their volumes. The concentration of BoNT / A in KS and DS was determined using a BoNT / A-specific ELISA. The total yield was calculated according to Equation 2 above.
[0170] For purified API batches #16852, #17043, and #19139, the overall yield was determined to be between 13% and 29% (data not shown). Example 13: Purity Improvement Factor (each step)
[0171] The purity improvement factor of BoNT / A at each individual method step serves as an indicator of the efficiency of each step (and the overall purification method) in removing unwanted protein components (method-related and product-related). To calculate the purity improvement factor for each step, the toxin concentration in each elution fraction was analyzed using a BoNT / A-specific ELISA, and the total protein concentration in each elution fraction was analyzed using a micro-BCA method (Example 4). The purity improvement for each step was calculated according to the following formula: (Equation 5)
[0172] Where ToxC is the toxin concentration, TotPC is the total protein concentration, the subscripted dissolution portion indicates the toxin concentration or total protein concentration obtained from the current processing step, and the previous dissolution portion indicates the toxin concentration or total protein concentration obtained from the previous processing step.
[0173] Figure 7 shows the average purity improvement factor for each step of the purified active pharmaceutical ingredient batches #16852, #17043, and #19139. The bars marked "DS" show the combined purity improvement factor of the two final chromatographic steps at their interconnection without sampling in between. Based on the data, it is evident that the second chromatographic column is the most helpful step in purifying the toxin. However, in terms of total protein concentration, all steps (except filtration 1, which removes intact or dissolved cells and cell components) contribute to the overall purification of the toxin. Example 14: Cumulative Purity Improvement Factor (each step)
[0174] The cumulative purity improvement factor for each individual method step is calculated as follows: (Equation 6) where ToxC is the toxin concentration, TotPC is the total protein concentration, the subscript "dissolved fraction" indicates the toxin concentration or total protein concentration obtained from the current processing step, and the subscript "KS" indicates the toxin concentration or total protein concentration obtained from the culture at collection time, wherein cells are removed by filtration through a 0.2 µm filter. The first method step of the purification method (fermentation at collection time) is set as a purity improvement factor of 1.
[0175] Figure 8 shows the average cumulative purity improvement factor for each step of the purified drug substance batches #16852, #17043 and #19139. The bars marked "DS" show the cumulative combined purity improvement factor of the two final chromatography steps when they are interconnected without sampling. [Simplified Explanation of the Diagram]
[0177] Figure 1 is a flowchart showing an embodiment of a method for purifying botulinum toxin composition from fermentation medium according to the present invention.
[0178] Figure 2 shows the SDS-PAGE results of the product toxin solution prepared according to the present invention stained with colloidal Coumarin blue.
[0179] Figure 3 shows the SDS-PAGE results of three different product toxin solutions prepared according to the present invention.
[0180] Figure 4 shows the SEC molecular weight distribution of the product toxin solution prepared according to the present invention.
[0181] Figure 5 shows the average processing yield of the three product toxin solutions prepared according to the present invention after a series of purification steps.
[0182] Figure 6 shows the average cumulative treatment yield of the three product toxin solutions prepared according to the present invention through a series of purification steps.
[0183] Figure 7 shows the average purity improvement factor of the three product toxin solutions prepared according to the present invention after undergoing successive purification steps.
[0184] Figure 8 shows the average cumulative purity improvement factor of the three product toxin solutions prepared according to the present invention after continuous purification steps.
Claims
1. A method for purifying botulinum toxin from a solution containing botulinum toxin, comprising: (a) filtering the solution containing the toxin; (b) contacting a first chromatography column with the filtered solution containing the toxin obtained in (a), wherein the first chromatography column is an anion exchange chromatography column and the filtered solution has a pH of 5.5 to 7; (c) collecting a toxin-containing elutite, wherein the toxin-containing elutite flows through the first chromatography column without adsorbing onto a stationary phase; (d) contacting a second chromatography column with the toxin-containing elutite, wherein the second chromatography column is a cation exchange chromatography column and the toxin-containing elutite has a pH of 4 to 5; (e) dissolving the botulinum toxin from the second chromatography column to produce a first toxin-containing elutite; and (f) filtering the first toxin-containing elutite to produce a toxin-containing retentate. (g) Contacting a third chromatography column with the toxin-containing retentate obtained from the filtration (f), wherein the third chromatography column is an anion exchange column and the toxin-containing retentate has a pH of 7.5 to 8.5; (h) Dissolving the botulinum toxin from the third chromatography column to produce a second toxin-containing precipitate; (i) Contacting a fourth chromatography column with the second toxin-containing precipitate, wherein the fourth chromatography column is a size exclusion chromatography column and the second toxin-containing precipitate has a pH of 6 to 7; and (j) Dissolving the botulinum toxin from the fourth chromatography column to produce purified botulinum toxin, wherein the method does not involve precipitation, centrifugation, or freeze-drying of the botulinum toxin, and wherein the botulinum toxin is botulinum neurotoxin serotype A.
2. The method of claim 1, wherein i) the purified botulinum toxin obtained is free of, substantially free of or substantially free of botulinum toxin complex; ii) the purified botulinum toxin obtained is free of, substantially free of or substantially free of animal products; and / or iii) the purified botulinum toxin is free of, substantially free of or substantially free of human albumin.
3. The method of claim 1 or 2, wherein the first chromatography column comprises Q agarose.
4. The method of claim 1 or 2, wherein the second chromatography column contains SP agarose.
5. The method of claim 1 or 2, wherein the first chromatography column contains Q agarose and the second chromatography column contains SP agarose.
6. The method of claim 1 or 2, wherein the third chromatography column contains Q agarose.
7. The method of claim 1 or 2, wherein the fourth chromatography column comprises a gel filtration column.
8. The method of request item 1 or 2, wherein the fourth chromatography column comprises Superdex 200.
9. The method of claim 1 or 2, wherein the third chromatography column comprises Q agarose and the fourth chromatography column comprises Superdex 200.
10. The method of claim 1 or 2, wherein the second toxin-containing elution solution is directly injected onto the fourth chromatography column; and / or wherein the third chromatography column is interconnected with the fourth chromatography column.
11. The method of claim 1 or 2, wherein the first chromatography column contains Q agarose, the second chromatography column contains SP agarose, the third chromatography column contains Q agarose, and the fourth chromatography column contains Superdex 200.
12. The method of request item 1 or 2, wherein the first, second, third and fourth chromatography columns are disposable chromatography systems.
13. The method of claim 1 or 2, wherein the filtration (f) is to dissociate botulinum toxin protein molecules from non-toxin proteins to produce free toxin molecules.
14. The method of request 1 or 2, wherein the filtration (f) includes buffer exchange.
15. The method of claim 1 or 2, wherein the solution containing botulinum toxin is a fermentation medium that is free of animal products, substantially free of animal products, or substantially free of animal products.
16. The method of claim 1 or 2, further comprising contacting the botulinum toxin with a buffer solution, wherein the buffer solution has been filtered to reduce the bioburden.
Citation Information
Patent Citations
Method of purifying botulinus toxin
JP2011074025A
